The Poolbeg-led consortium will receive €2.3 million in government grants to develop a next-generation oral vaccine

EncOVac, a consortium led by Poolbeg Pharma, has received €2.3 million in funding from the Irish Government’s Disruptive Technologies Innovation Fund (DTIF).

oolbeg Pharma is an infectious disease company formed from Irish vaccine research company Open Orphan.

Through the grant funding, Poolbeg will now work with researchers from University College Dublin and Trinity College Dublin and Dublin-based company Anabio Technologies to develop the next generation of oral vaccine technologies.

Professor Luke O’Neill, who became a media figure during the Covid-19 pandemic, will serve as Advisory Chair for the project. He is also a non-executive director at Poolbeg Pharma.

This grant is one of 11 Irish projects funded by DTIF today. The state fund invested €40 million in these projects, which focus on a range of areas including machine learning, health and robotics.

Each of the 11 selected projects received funding of between 1.5 and 7 million euros.

The EUR 500 million fund was first set up as part of the National Development Plan in 2018 and has so far been approved with EUR 275 million.

“The funding will support the advancement of this exciting oral vaccine platform, which has the potential to improve vaccine manufacturing, distribution and delivery for the future,” said Jeremy Skillington, Chief Executive of Poolbeg.

“Poolbeg continues to target non-dilutive funding opportunities and we are pleased that this DTIF award is our first achievement.”

Oral vaccines produce a reaction in areas of the body where infection can enter, such as the B. nose or mouth. According to Poolbeg, this type of vaccination can also ease challenges in vaccination distribution.

“Oral vaccines are currently only available to treat a small number of pathogens and a more comprehensive approach to vaccine development is needed to design new, safe and effective oral vaccines,” said Professor O’Neill.

“Such a system would revolutionize our approach to protecting people from infectious diseases and unleash their full potential.”

The consortium will work on the development of the oral vaccine over the next three years and plans to advance a vaccine candidate to a phase I-ready state. Phase I trials of a new drug are usually the first phases in which people are involved. The Poolbeg-led consortium will receive €2.3 million in government grants to develop a next-generation oral vaccine

Fry Electronics Team

Fry is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button